Is DexCom Stock Underperforming the Nasdaq?

Company Overview - DexCom, Inc. is a medical device company based in San Diego, California, specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management [1] - The company has a market capitalization of $28.1 billion, positioning it as a large-cap stock within the medical devices industry [2] Stock Performance - DXCM stock reached a 52-week high of $89.98 on July 30, 2025, but has since declined by 19% from that peak [3] - Over the past three months, the stock has gained 11.7%, outperforming the Nasdaq Composite, which has slipped by 3% during the same period [3] - In the longer term, DXCM has declined by 11.6% over the past 52 weeks, underperforming the Nasdaq Composite's return of 24.7% [3] Trading Indicators - The stock has been trading below its 200-day moving average since last year, with fluctuations, but has remained above its 50-day moving average since mid-February [4] Financial Performance - Following the release of better-than-expected Q4 2025 earnings, DXCM stock surged by 7.6% [5] - The company's revenue grew nearly 13% year-over-year to $1.3 billion, surpassing Wall Street estimates [5] - Adjusted EPS for the quarter was $0.68, also exceeding expectations, and the company anticipates revenue for the next fiscal year to be between $5.2 billion and $5.3 billion, indicating an annual growth of 11% to 13% [5] Analyst Sentiment - Compared to its closest peer, STERIS plc, which has increased by 7.6% over the past year, DXCM has underperformed [6] - Wall Street analysts maintain a favorable view of DXCM, with a consensus rating of "Strong Buy" among 28 analysts and a mean price target of $85.36, suggesting a 17.1% upside potential from current levels [6]